---
schema_version: "secwatch.filing_event.v1"
accession: "0001575872-23-000296"
form_type: "8-K"
ticker: "ESLA"
cik: "0001844417"
company_name: "Estrella Immunopharma, Inc."
filed_at: "2023-02-21T23:59:59+00:00"
generated_at: "2026-06-19T07:17:23.947590+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# TradeUP Acquisition Corp. Extends Business Combination Deadline to March 19, 2023 with Estrella Biopharma Deposit

## Summary
- Estrella Biopharma deposited $45,511 into TradeUP's trust account to extend the business combination deadline from February 19 to March 19, 2023.
- TradeUP issued an unsecured promissory note (Extension Note) to Estrella for the deposit amount, bearing no interest and payable upon business combination.
- Estrella has the right to convert the Extension Note into shares of TradeUP common stock at $10.00 per share.
- The extension is part of the Merger Agreement dated September 30, 2022, and allows monthly extensions up to July 19, 2023.
- The Extension Note was issued under exemption from registration under Section 4(a)(2) of the Securities Act.

## SEC filing metadata
- accession: 0001575872-23-000296
- form_type: 8-K
- ticker: ESLA
- cik: 0001844417
- company_name: Estrella Immunopharma, Inc.
- filed_at: 2023-02-21T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 2.03, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1844417/000157587223000296/0001575872-23-000296-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1844417/000157587223000296/uptd-20230123.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001575872-23-000296
- JSON: https://secwatch.observer/filing/0001575872-23-000296.json
- Plain text: https://secwatch.observer/filing/0001575872-23-000296.txt

## Key facts
- Debt Financings
  Estrella Immunopharma, Inc. incurred loan of $45,511 with Estrella Biopharma, Inc. at no interest maturing upon the consummation of the Company's business combination.
  - Instrument: loan
  - Principal: $45,511
  - Counterparty: Estrella Biopharma, Inc.
  - Rate: no interest
  - Maturity: upon the consummation of the Company's business combination
  - Event: incurrence
  source text: Estrella has deposited a monthly extension payment of $45,511 to the trust account of the Company to extend the deadline for the Company to complete the business combination contemplated therein by March 19, 2023. Such deposit is evidenced by an unsecured promissory note in the principal amount of o $45,511issued by the Company to Estrella (the “Extension Note”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1844417/000157587223000296/0001575872-23-000296-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.